BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

UK's National Institute for Clinical Excellence (NICE) Rejects Genentech (RHHBY)'s Avastin for Ovarian Cancer


2/1/2013 6:58:12 AM

Roche Holding AG (ROG)’s anti-tumor drug Avastin failed for the second time in two months to win the backing of the U.K.’s health-cost regulator as a treatment for ovarian cancer in a draft decision issued today. The National Institute for Health and Clinical Excellence recommended against the drug as an initial treatment for women with ovarian cancer that has spread beyond the ovarian lining and then returned six months or more after first being treated with platinum-based chemotherapy. The guidance also covers fallopian tube and primary peritoneal cancer, NICE said. Though Avastin “may help to delay the spread of a patient’s cancer for a limited time,” there wasn’t evidence to show the drug’s benefit justified its cost, Andrew Dillon, NICE’s chief executive, said in the statement. National Health Service patients have other options for treatment, Dillon said. Today’s recommendation comes after NICE refused on Dec. 18 to back Avastin for use after ovarian cancer has initially spread. Ovarian is one of the types of cancer Roche has said will drive sales growth for Avastin. The agency in December said it wasn’t clear whether the drug helped women live longer.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->